Personas / Equipo Humano

Clàudia Fortuny Guasch

Buscador de publicaciones

Publicaciones

  • Polo R, García-Albéniz X, Terán C, Morales M, Rial-Crestelo D, Garcinuño MA, García Del Toro M, Hita C, Gómez-Sirvent JL, Buzón L, Díaz de Santiago A, Pérez Arellano JL, Sanz J, Bachiller P, Martínez Alfaro E, Diaz de Brito V, Masiá M, Hernández-Torres A, Guerra J, Santos J, Arazo P, Muñoz L, Arribas JR, Martínez de Salazar P, Moreno S, Hernán MA, Del Amo J, Del Amo J, Rosa Polo, Moreno S, Berenguer J, Martínez E, Hernán M, Martínez de Salazar P and García de Albéniz X.

    Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo-controlled randomized trial in healthcare workers

    CLINICAL MICROBIOLOGY AND INFECTION . 29(1): 85-93. Nº de citas: 11

    [doi:10.1016/j.cmi.2022.07.006]

  • Epalza C, Domínguez-Rodríguez S, Cervantes E, Jiménez de Ory S, Frick MA, Fortuny-Guasch C, Soler-Palacín P, Prieto-Tato L, Sainz T, Carreras-Abad C, Montero Alonso M, de Zárraga Fernández MA, Ocampo A, Rojo P and Navarro ML.

    Factors associated with late presentation for HIV care in adolescents in Spain.

    HIV MEDICINE . 23(11): 1195-1201. Nº de citas: 4

    [doi:10.1111/hiv.13407]

  • Velasco E, Batllori-Tragant M, Manuel Monsonis Cabedo, Valls-Lafon A, Rios-Barnés M, Simó-Nebot S, Gamell Fullà A, Fortuny-Guasch C, Tebruegge M and Noguera-Julian A.

    Host, technical, and environmental factors affecting QuantiFERON-TB Gold In-Tube performance in children below 5 years of age

    SCIENTIFIC REPORTS . 12(1): 19908-19908. Nº de citas: 4

    [doi:10.1038/s41598-022-24433-w]

  • Mele-Casas M, Launes-Montana C, Fernández de Sevilla-Estrach M, Hernandez-Garcia M, Pons-Tomas G, Bassat Q, Fumadó V, Fortuny-Guasch C, Garcia-Miquel A, Bonet E, Prats C, Ajanovic S, Cubells M, Claverol J, Penela-Sanchez D, Jou-Munoz C, Arias S, Balanza N, Baro B, Millat-Martinez P, Alonso S, Alvarez-Lacalle E, Catala M, Cuadras-Palleja D, Munoz-Almagro C, Gratacós E, Jordán-García I and García-García JJ.

    Low transmission of SARS-CoV-2 derived from children in family clusters: An observational study of family households in the Barcelona Metropolitan Area, Spain

    PLoS One . 17(11): . Nº de citas: 5

    [doi:10.1371/journal.pone.0277754]

  • Goncé A, Hawkins-Villarreal A, Salazar L, Guirado L, Marcos MA, Pascual Mancho J, Prats P, López M, Eixarch E, Salvia MD, Fortuny-Guasch C and Figueras-Retuerta F.

    Maternal high-dose valacyclovir and its correlation with newborn blood viral load and outcome in congenital cytomegalovirus infection

    JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE . 35(20): 4004-4008. Nº de citas: 7

    [doi:10.1080/14767058.2020.1843016]

  • Torres-Fernandez D, Jiménez de Ory S, Fortuny-Guasch C, Sainz T, Falcón D, Bernal E, Jiménez MC, Vilasaró MN, Epalza C, Navarro M, Ramos JT, Holguín Á and Prieto L.

    Integrase inhibitors in children and adolescents: clinical use and resistance

    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY . 77(10): 2784-2792. Nº de citas: 5

    [doi:10.1093/jac/dkac259]

  • Turkova A, Waalewijn H, Chan MK, Bollen PDJ, Bwakura-Dangarembizi MF, Kekitiinwa AR, Cotton MF, Lugemwa A, Variava E, Ahimbisibwe GM, Srirompotong U, Mumbiro V, Amuge P, Zuidewind P, Ali S, Kityo CM, Archary M, Ferrand RA, Violari A, Gibb DM, Burger DM, Ford D and Colbers A.

    Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

    Lancet HIV . 9(9): 627-637. Nº de citas: 21

    [doi:10.1016/S2352-3018(22)00160-6]

  • Amuge P, Lugemwa A, Wynne B, Mujuru HA, Violari A, Kityo CM, Archary M, Variava E, White E, Turner RM, Shakeshaft C, Ali S, Nathoo KJ, Atwine L, Liberty A, Bbuye D, Kaudha E, Mngqibisa R, Mosala M, Mumbiro V, Nanduudu A, Ankunda R, Maseko L, Kekitiinwa AR, Giaquinto C, Rojo P, Gibb DM, Turkova A and Ford D.

    Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial

    Lancet HIV . 9(9): 638-648. Nº de citas: 23

    [doi:10.1016/S2352-3018(22)00163-1]

  • Ortiz-Gracia A, Rios-Barnés M, Tobías E, Noguera-Julian A, García-García FJ, Cantó-Santos J, Valls-Roca L, Garrabou G, Grau JM, Cardellach F, Sánchez E, Morén C and Fortuny-Guasch C.

    Assessment of mitochondrial toxicity in newborns and infants with congenital cytomegalovirus infection treated with valganciclovir

    ARCHIVES OF DISEASE IN CHILDHOOD . 107(7): 686-691.

    [doi:10.1136/archdischild-2021-322996]

  • Simó-Nebot S, López-Ramos MG, Velasco E, Jordán-García I, Fortuny-Guasch C and Noguera-Julian A.

    Impact and quality of antimicrobial use in a referral pediatric intensive care unit.

    enfermedades infecciosas y microbiologia clinica (english ed.) . 40(2): 78-81.

    [doi:10.1016/j.eimce.2021.05.013]